BRIEF published on 11/04/2024 at 11:51, 1 year 9 months ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 1 year 9 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 9 months ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 9 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 10 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 1 year 10 months ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 10 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 10 months ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 2 years 1 month ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 2 years 1 month ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 08/19/2026 at 04:00, 2 hours 32 minutes ago Momenta, XHEART, and QNX Build an Autonomous Driving Platform Certified to Global Safety Standards
Published on 08/18/2026 at 23:10, 7 hours 22 minutes ago Secure Blockchain Signs Agreement to Sell Delivery Trust(R) Business
Published on 08/18/2026 at 19:45, 10 hours 47 minutes ago ECC Ventures 5 Corp. Enters Into Business Combination Agreement with Bayrock Resources for Qualifying Transaction
Published on 08/18/2026 at 18:30, 12 hours 2 minutes ago Sterling Metals Announces Approval of Arrangement by QcX Gold Shareholders
Published on 08/18/2026 at 17:40, 12 hours 52 minutes ago Largo Physical Vanadium Announces Postponement of Annual Meeting
Published on 08/19/2026 at 06:00, 31 minutes ago Résultat semestriel 2026 : Implenia augmente sa rentabilité, son carnet de commandes et son flux de trésorerie disponible
Published on 08/19/2026 at 06:00, 31 minutes ago Half-year results 2026: Implenia increases profitability, order book and free cash flow
Published on 08/18/2026 at 22:00, 8 hours 32 minutes ago Enlight Research publishes updated coverage on Eleving Group
Published on 08/18/2026 at 21:50, 8 hours 41 minutes ago Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Published on 08/18/2026 at 19:00, 11 hours 32 minutes ago HIAG strengthens sustainable financing with third green bond worth CHF 100 million
Published on 08/18/2026 at 18:00, 12 hours 32 minutes ago KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 12 hours 47 minutes ago Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 19 hours 16 minutes ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 19 hours 16 minutes ago GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 1 day 10 hours ago Aéroports de Paris S.A - July 2026 traffic figures
